Relating to prohibited direct-to-consumer pharmaceutical advertising; providing an administrative penalty.

The provided context does not include the actual text or substantive details of HB 4586. While the title mentions restrictions on direct-to-consumer pharmaceutical advertising and administrative penalties, no specific provisions, affected parties, or mechanisms are described in the available information. The bill's recent actions (filed, read first time, referred to Public Health) do not clarify its content. Without the bill text or summary, a factual policy description cannot be provided.